Elevated levels of circulating YKL-40 are related to poor outcome or short disease-free survival in glioblastoma, melanoma, ovarian, breast, colon, lung, and prostate cancers in humans (52, 84–92). Here, CHI3L1 is linked to prostate carcinoma.